Cover Image

CRS and HIPEC for pancreatic ductal adenocarcinoma with peritoneal metastases: a case report

Background: Pancreatic ductal adenocarcinoma (PDAC) is aggressive, with more than 80% present with metastatic disease, and an overall survival of less than a year with systemic chemotherapy treatment. Cytoreductive surgery (CRS) and intraperitoneal chemotherapy are two treatment modalities being exp...

Full description

Saved in:
Bibliographic Details
Main Authors: Amin-Tai, Hizami, Adznan, Muhammad Ash-Shafhawi, Canda, Aras Emre, Yılmaz, Hüseyin Cahit, Kılıç, Murat, Terzi, Mustafa Cem
Format: Article
Language:English
Published: Surgical Society of North Greece 2023
Online Access:http://psasir.upm.edu.my/id/eprint/107180/1/CRS%20and%20HIPEC%20for%20pancreatic%20ductal%20adenocarcinoma%20with%20peritoneal%20metastases.pdf
http://psasir.upm.edu.my/id/eprint/107180/
https://www.surgchronicles.gr/components/com_journals/journals/2023/4/22.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
id my.upm.eprints.107180
record_format eprints
spelling my.upm.eprints.1071802024-10-17T03:44:45Z http://psasir.upm.edu.my/id/eprint/107180/ CRS and HIPEC for pancreatic ductal adenocarcinoma with peritoneal metastases: a case report Amin-Tai, Hizami Adznan, Muhammad Ash-Shafhawi Canda, Aras Emre Yılmaz, Hüseyin Cahit Kılıç, Murat Terzi, Mustafa Cem Background: Pancreatic ductal adenocarcinoma (PDAC) is aggressive, with more than 80% present with metastatic disease, and an overall survival of less than a year with systemic chemotherapy treatment. Cytoreductive surgery (CRS) and intraperitoneal chemotherapy are two treatment modalities being explored to improve the survival rates of these patients. Case presentation: A 45-year-old man presented with epigastric pain, mass, and weight loss. Investigations revealed a pancreatic tumour with liver and extensive peritoneal metastases. After 18 cycles of chemotherapy, there was significant disease regression which allowed CRS and HIPEC to be performed. HIPEC, PIPAC, and repeated intraperitoneal liquid chemotherapy have been shown to be safe. Longer survival and reduced disease related complications are among the advantages seen in published data. Conclusion: Complete cytoreduction and HIPEC, repeated cycles of either intraperitoneal chemotherapy or PIPAC, are associated with longer survival and reasonable adverse effects. Patients diagnosed with PDAC and peritoneal metastases should be considered for these treatment strategies. Surgical Society of North Greece 2023-10 Article PeerReviewed text en http://psasir.upm.edu.my/id/eprint/107180/1/CRS%20and%20HIPEC%20for%20pancreatic%20ductal%20adenocarcinoma%20with%20peritoneal%20metastases.pdf Amin-Tai, Hizami and Adznan, Muhammad Ash-Shafhawi and Canda, Aras Emre and Yılmaz, Hüseyin Cahit and Kılıç, Murat and Terzi, Mustafa Cem (2023) CRS and HIPEC for pancreatic ductal adenocarcinoma with peritoneal metastases: a case report. Surgical Chronicles, 28 (4). pp. 460-463. ISSN 1108-5002 https://www.surgchronicles.gr/components/com_journals/journals/2023/4/22.pdf
institution Universiti Putra Malaysia
building UPM Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Universiti Putra Malaysia
content_source UPM Institutional Repository
url_provider http://psasir.upm.edu.my/
language English
description Background: Pancreatic ductal adenocarcinoma (PDAC) is aggressive, with more than 80% present with metastatic disease, and an overall survival of less than a year with systemic chemotherapy treatment. Cytoreductive surgery (CRS) and intraperitoneal chemotherapy are two treatment modalities being explored to improve the survival rates of these patients. Case presentation: A 45-year-old man presented with epigastric pain, mass, and weight loss. Investigations revealed a pancreatic tumour with liver and extensive peritoneal metastases. After 18 cycles of chemotherapy, there was significant disease regression which allowed CRS and HIPEC to be performed. HIPEC, PIPAC, and repeated intraperitoneal liquid chemotherapy have been shown to be safe. Longer survival and reduced disease related complications are among the advantages seen in published data. Conclusion: Complete cytoreduction and HIPEC, repeated cycles of either intraperitoneal chemotherapy or PIPAC, are associated with longer survival and reasonable adverse effects. Patients diagnosed with PDAC and peritoneal metastases should be considered for these treatment strategies.
format Article
author Amin-Tai, Hizami
Adznan, Muhammad Ash-Shafhawi
Canda, Aras Emre
Yılmaz, Hüseyin Cahit
Kılıç, Murat
Terzi, Mustafa Cem
spellingShingle Amin-Tai, Hizami
Adznan, Muhammad Ash-Shafhawi
Canda, Aras Emre
Yılmaz, Hüseyin Cahit
Kılıç, Murat
Terzi, Mustafa Cem
CRS and HIPEC for pancreatic ductal adenocarcinoma with peritoneal metastases: a case report
author_facet Amin-Tai, Hizami
Adznan, Muhammad Ash-Shafhawi
Canda, Aras Emre
Yılmaz, Hüseyin Cahit
Kılıç, Murat
Terzi, Mustafa Cem
author_sort Amin-Tai, Hizami
title CRS and HIPEC for pancreatic ductal adenocarcinoma with peritoneal metastases: a case report
title_short CRS and HIPEC for pancreatic ductal adenocarcinoma with peritoneal metastases: a case report
title_full CRS and HIPEC for pancreatic ductal adenocarcinoma with peritoneal metastases: a case report
title_fullStr CRS and HIPEC for pancreatic ductal adenocarcinoma with peritoneal metastases: a case report
title_full_unstemmed CRS and HIPEC for pancreatic ductal adenocarcinoma with peritoneal metastases: a case report
title_sort crs and hipec for pancreatic ductal adenocarcinoma with peritoneal metastases: a case report
publisher Surgical Society of North Greece
publishDate 2023
url http://psasir.upm.edu.my/id/eprint/107180/1/CRS%20and%20HIPEC%20for%20pancreatic%20ductal%20adenocarcinoma%20with%20peritoneal%20metastases.pdf
http://psasir.upm.edu.my/id/eprint/107180/
https://www.surgchronicles.gr/components/com_journals/journals/2023/4/22.pdf
_version_ 1814054624076759040
score 13.211869

Similar Items